Dienogest Vs Gnrh Agonists As Postoperative Therapy After Laparoscopic Eradication Of Deep Infiltrating Endometriosis With Bowel And Parametrial Surgery: A Randomized Controlled Trial

Background The recurrence of deep infiltrating endometriosis (DIE) after its surgical excision is a big problem: postoperative treatment is crucial. Objective To compare two postoperative treatments: Dienogest and GnRH agonists. Design Prospective Randomized Controlled Trial (RCT). Patients 146 women submitted to laparoscopic eradication of DIE with bowel and parametrial surgery. Interventions Patients were randomized into two groups. Group A (n = 81) received Triptorelin or Leuprorelin 3.75 mg every 4 weeks for 6 months. Group B (n = 65) received Dienogest 2 mg/day for at least 6 months. A first interview made after six months valued compliance to therapy, treatment tolerability, pain improvement, and side effects. A second interview at 30 +/- 6 months valued pain relapse, imaging relapse, and pregnancy rate. Main outcomes The primary outcome was to demonstrate the non-inferiority of Dienogest about the reduction in pain recurrence. Secondary outcomes were differences in terms of treatment tolerability, side effects, imaging relapse rate, and pregnancy rate. Results Both Dienogest and GnRH agonists were associated with a highly significant reduction of pain at 6 and 30 months, without any significant difference (p < .001). About treatment tolerability, a more satisfactory profile was reported with Dienogest (p = .026). No difference in terms of clinical relapse, imaging relapse, and live births was found. Conclusions Dienogest has proven to be as effective as GnRH agonists in preventing recurrence of DIE and associated pelvic pain after surgery. Also, it is better tolerated by patients.